100 Migraine drugs, A to Z: Atenolol

June 4, 2018

Atenolol (Tenormin) is a blood pressure medicine in the beta blocker family. Atenolol is considered to be equally effective in preventing migraines to propranolol (Inderal), which was the first drug to be approved for the prevention of migraines over 50 years ago. The effect of atenolol lasts all day and it can be taken once a day. It has the same side effect profile as propranolol. The most common side effects are caused by excessive lowering of blood pressure or slowing of the pulse rate and include fatigue, lightheadedness, exercise intolerance, cold extremities, and occasionally impotence, depression and insomnia. Some but not all beta blockers can worsen asthma.

You do not have to have high blood pressure to take atenolol or another beta blocker – they prevent migraines even if blood pressure is normal. We still do not know how these drugs prevent migraines. We do not prescribe beta blockers if the blood pressure is low (below 110/70) because the risk of side effects is high. However, if the blood pressure is in the middle of normal range or higher, this is a good choice. Beta blockers also help with anxiety and many performers take them only before giving a speech, a presentation, or a musical performance. Under these circumstances, a short-acting beta blocker, such as propranolol is a better choice than atenolol. Beta blockers are also very effective for the benign essential or familial tremor.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe